ArticleNPJ breast cancer2026

Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profiling.

Ting Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.